tirzepatide surpass Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Overview of the SURPASS clinical

Many patients may need long-term treatment to maintain results because obesity is a chronic condition, Dr Kaddaha adds

Inadequate protein during rapid fat loss leads to lean mass loss alongside fat loss, reducing the quality of the final body composition result

An important mechanistic question also remains unanswered: did tirzepatide directly cause the molecular changes we observed, or did they simply result from reduced alcohol intake

Eli Lilly is also launching the Zepbound Self Pay Journey Program, which lowers the price of a patients first prescription of the 7.5 mg or 10 mg vials to $499, along with any refills made within 45 days of the previous prescription cycle